Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific reports further growth in third quarter of 2017

Boston Scientific reports further growth in third quarter of 2017

1st November 2017

Boston Scientific has announced its financial results for the third quarter of 2017, reporting a sales total of $2.22 billion (1.67 billion pounds).

This represented a year-on-year increase of 5.6 percent on a reported basis and 5.7 percent on an operational basis, with organic revenue growth calculated at 4.3 percent when factoring out the recent acquisitions of EndoChoice and Symetis.

Revenue growth was reflected across all regions, with key highlights of the quarter including the receipt of US approval for the Resonate family of defibrillators and EU approval for the Acurate Neo valve system and Watchman left atrial appendage closure device.

The firm also completed the acquisition of Apama Medical, a privately-held medical technology company that is developing a new treatment for atrial fibrillation.

For the full year, revenues in the range of $8.99 billion to $9.02 billion are now expected, which would represent year-on-year growth of seven to eight percent.

Mike Mahoney, chairman and chief executive officer of Boston Scientific, said: "Our global team is delivering strong performance as we continue to invest in a deep and innovative portfolio and expand into faster-growing markets."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.